Here's Why Aimmune Therapeutics Fell 7% Today
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
Aimmune Therapeutics
AIMT
AIMT
$18.03
-$0.96
0.0%
BATS BZX Real Time Price as of July 18, 2019, 3:54 p.m. EDT
View Interactive AIMT Charts
Aimmune Therapeutics, Inc.
News & Analysis: Aimmune Therapeutics
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Aimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Call Transcript
AIMT earnings call for the period ending March 31, 2019.
4 Blockbuster Drug Launches to Watch in 2019
These four experimental drugs will reach the market soon, and the companies launching them have little room for error.
3 Top Biotech Stocks to Buy Right Now
Biotech may be a tough industry to invest in, but we've found three companies within that space that are worth looking into.
3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown
No funding for the FDA means delays in drug reviews and approvals. And that could translate to bad news for these three biotechs.
3 Potential New Drugs Held Up by the Shutdown
The market's about to find out the FDA does a lot more than check lettuce.
Why Tilray, Fortuna Silver Mines, and Aimmune Therapeutics Jumped Today
These stocks managed to avoid the market's broad sell-off.
Here's Why Aimmune Therapeutics Closed Down 11.2% After Publishing Its "Landmark" Clinical Trial
Balancing efficacy and safety is hard.
Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today
One biotech's phase 3 failure benefits its competitor.
